METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS, SCLERODERMA, AND MYOSITIS WITH AN ANTIBODY AGAINST INTERFERON-ALPHA

摘要

The disclosure relates to methods of treating systemic lupus erythematosus, scleroderma, and myositis comprising the administration of an anti-interferon-alpha antibody. Specifically, the disclosure provides weight-based and fixed dose administration regimes based on pharmacokinetic characteristics. Further disclosed are sequences of complementarity determining regions (CDRs) of heavy chain and light chain variable regions of the antibody. The methods of suppressing an interferon (I FN) pharmacodynamic signature are also provided.